600713.SHG NanJing Pharmaceutical Co Ltd
- Market cap
- CNY 6.93B
- P/E
- 12.3x
- P/B
- 0.95x
- ROE
- 7.6%
- Dividend yield
- 7.11%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600713.SHG undervalued?
Graham number600713.SHG trades 27.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NanJing Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for NanJing Pharmaceutical Co Ltd yet.
NanJing Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NanJing Pharmaceutical Co Ltd
Nanjing Pharmaceutical Group Company Limited engages in the distribution of pharmaceuticals, medical devices, and health products in China. It also involved in the wholesale and retail of pharmaceuticals; provision of internet + Chinese medicine pharmacy service platform; and pharmaceutical third-party logistics services. The company was formerly known as NanJing Pharmaceutical Company Limited and change its name to Nanjing Pharmaceutical Group Company Limited in December 20…
Full company profileNanJing Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NanJing Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 26.7B | 28.8B | 31.3B | 37.2B | 39.8B | 45.1B | 50.2B | 53.6B | 53.7B | 55.0B | 55.6B |
| Gross Profit | 1.57B | 1.85B | 2.07B | 2.46B | 2.52B | 2.93B | 3.25B | 3.31B | 3.35B | 3.38B | 3.41B |
| Operating Income | 347M | 425M | 480M | 529M | 676M | 846M | 934M | 1.01B | 1.02B | 1.53B | 1.62B |
| EBITDA | 648M | 791M | 933M | 1.15B | 1.19B | 1.44B | 1.51B | 1.68B | 1.67B | 1.74B | 1.30B |
| Net Income | 180M | 232M | 264M | 347M | 376M | 505M | 596M | 578M | 571M | 625M | 554M |
| EPS | 0.20 | 0.26 | 0.26 | 0.33 | 0.36 | 0.49 | 0.48 | 0.45 | 0.44 | 0.48 | 0.42 |
| Balance Sheet | |||||||||||
| Total Assets | 14.0B | 15.9B | 19.6B | 22.0B | 23.4B | 25.9B | 31.7B | 28.4B | 30.7B | 31.4B | 38.7B |
| Total Liabilities | 10.9B | 12.7B | 15.4B | 17.4B | 18.6B | 20.7B | 25.0B | 21.2B | 22.9B | 23.2B | 29.9B |
| Shareholders' Equity | 2.63B | 2.78B | 3.67B | 4.01B | 4.26B | 4.61B | 6.00B | 6.44B | 6.84B | 7.19B | 7.26B |
| Cash & Short-term Investments | 1.21B | 1.85B | 2.27B | 2.10B | 1.48B | 2.09B | 2.33B | 2.37B | 4.56B | 3.05B | 1.88B |
| Total Debt | 1.77B | 5.23B | 3.10B | 3.16B | 6.32B | 6.50B | 5.61B | 11.6B | 7.50B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -241M | 320M | -367M | 1.00B | -1.15B | 695M | -682M | 1.91B | 2.14B | 91.8M | - |
| Capital Expenditure | 196M | 241M | 312M | 301M | 247M | 307M | 155M | 158M | 545M | 251M | 188M |
| Free Cash Flow | -437M | -52.9M | -678M | 703M | -1.40B | 389M | -838M | 1.75B | 1.59B | -160M | -8.94B |
| Ratios | |||||||||||
| ROE | 6.9% | 8.4% | 7.2% | 8.6% | 8.8% | 11.0% | 9.9% | 9.0% | 8.3% | 8.7% | 7.6% |
| ROA | 1.3% | 1.5% | 1.4% | 1.6% | 1.6% | 2.0% | 1.9% | 2.0% | 1.9% | 2.0% | 1.4% |
| Net Profit Margin | 0.7% | 0.8% | 0.8% | 0.9% | 0.9% | 1.1% | 1.2% | 1.1% | 1.1% | 1.1% | 1.0% |
| Debt to Equity | 0.67x | 1.88x | 0.84x | 0.79x | 1.48x | 1.41x | 0.93x | 1.81x | 1.10x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
NanJing Pharmaceutical Co Ltd dividends
- Dividend yield
- 7.11%
- Forward dividend
- 0.26 CNY
- Payout ratio
- 78.8%
- Ex-dividend date
- Sep 17, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 493M | 0.38 | 78.8% |
| 2024 | CNY 505M | 0.39 | 88.5% |
| 2023 | CNY 588M | 0.45 | 101.8% |
| 2022 | CNY 483M | 0.39 | 81.1% |
| 2021 | CNY 935M | 0.90 | 185.1% |
| 2020 | CNY 353M | 0.34 | 93.7% |
| 2019 | CNY 501M | 0.48 | 144.4% |
| 2018 | CNY 369M | 0.36 | 139.6% |
| 2017 | CNY 369M | 0.41 | 158.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Jul 8, 2011.
Who owns NanJing Pharmaceutical Co Ltd
- Insiders 59.50%
- Institutions 2.26%
- Public & others 38.25%
- Shares outstanding 1.31B
- Free float 561M
NanJing Pharmaceutical Co Ltd company profile
- Company name
- NanJing Pharmaceutical Co Ltd
- Ticker
- 600713.SHG
- ISIN
- CNE000000KV1
- Exchange
- Shanghai Stock Exchange
- Listed since
- Jun 7, 1996
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 4,697
- Fiscal year end
- December
- Address
- Building 2, Nanjing, China, 210012
- Phone
- 86 25 8455 2606
- Website
- njyy.com
About NanJing Pharmaceutical Co Ltd
Nanjing Pharmaceutical Group Company Limited engages in the distribution of pharmaceuticals, medical devices, and health products in China. It also involved in the wholesale and retail of pharmaceuticals; provision of internet + Chinese medicine pharmacy service platform; and pharmaceutical third-party logistics services. The company was formerly known as NanJing Pharmaceutical Company Limited and change its name to Nanjing Pharmaceutical Group Company Limited in December 2025. Nanjing Pharmaceutical Group Company Limited was founded in 1951 and is based in Nanjing, China.
NanJing Pharmaceutical Co Ltd management
9- Mr. Liang ZhangPresident & Director · born 1973
- Mr. Jian Sun CPAChief Accountant & Financial Director · born 1974
- Mr. Wen Jun LiVice President · born 1972
- Mr. Guan WangSecretary of the Board · born 1983
- Mr. Chuang FengVice President · born 1975
- Mr. Hong XiaoVice President · born 1977
- Ms. Yuping PengVice President · born 1980
- Ms. Qing YangChief Auditor & Supervisor · born 1972
- Ms. Xia YaoEmployee Supervisor & VP · born 1973